X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The net proceeds will be used to support a Phase 1 clinical study of the Company’s lead program PRN-001-01 (tezampanel), a novel modulator of glutaminergic signaling designed to treat patients seeking to recover from opioid addiction and associated conditions.
Lead Product(s): Tezampanel
Therapeutic Area: Psychiatry/Psychology Product Name: PRN-001-01
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Accelerator Life Science Partners
Deal Size: $9.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing February 01, 2024
Details:
The grant supports development of the company’s proprietary molecule, tezampanel, as a treatment for opioid withdrawal syndrome. Tezampanel has demonstrated positive results in a variety of preclinical models of seizure disorder in clinical studies.
Lead Product(s): Tezampanel
Therapeutic Area: Psychiatry/Psychology Product Name: LY-293,558
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute on Drug Abuse
Deal Size: $12.3 million Upfront Cash: Undisclosed
Deal Type: Funding September 17, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
